CPRX Catalyst Pharmaceuticals
- 16.490
- +0.090+0.55%
- 16.770
- +0.280+1.70%
Catalyst Pharmaceuticals News
Catalyst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Catalyst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The Catalyst Pharmaceuticals (CPRX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $24.00 to $26.00.
HC Wainwright & Co. : The Catalyst Pharmaceuticals (CPRX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $24.00 to $26.00.
HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $26
HC Wainwright & Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals with a Buy and raises the price target from $24 to $26.
Catalyst Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 67.2% HC Wainwright & Co. $24 → $26 Maintains Buy 03/27/2024 86.5% Oppenheimer $29 → $29 Reiter
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript
Catalyst Pharmaceuticals | 10-Q: Quarterly report
Catalyst Pharmaceuticals Reaffirms FY24 Total Revenue Guidance In The Range Of $455M-$475M Vs $460.53M Est
Reaffirm the 2024 full-year total revenue guidance in the range of $455 million and $475 million.
Catalyst Pharmaceuticals 1Q Adj EPS 38c >CPRX
Catalyst Pharmaceuticals 1Q Adj EPS 38c >CPRX
Catalyst Pharmaceuticals 1Q Rev $98.5M >CPRX
Catalyst Pharmaceuticals 1Q Rev $98.5M >CPRX
Catalyst Pharmaceuticals Backs FY24 Rev $455M-$475M >CPRX
Catalyst Pharmaceuticals Backs FY24 Rev $455M-$475M >CPRX
Catalyst Pharmaceuticals Q1 Adj $0.38 Beats $0.17 Estimate, Sales $98.51M Beat $98.13M Estimate
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.17 by 123.53 percent. This is a 7.32 percent decrease over earning
Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Posts Q1 EPS $0.38, Vs. Street Est of $0.30
04:18 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (CPRX) CATALYST PHARMACEUTICALS Posts Q1 EPS $0.38, vs. Street Est of $0.30
Catalyst Pharmaceuticals 1Q EPS 19c >CPRX
Catalyst Pharmaceuticals 1Q EPS 19c >CPRX
Press Release: Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Excepti
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial ProductsFIRDAPSE Q1 2024 Net Product Revenues of $66.8
Recent 3.3% Pullback Isn't Enough to Hurt Long-term Catalyst Pharmaceuticals (NASDAQ:CPRX) Shareholders, They're Still up 366% Over 5 Years
We think all investors should try to buy and hold high quality multi-year winners. While not every stock performs well, when investors win, they can win big. Just think about the savvy investors who
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
20 Companies Screened for Quality in a Cheap -2-
CarGurus Inc. Class A CARG 13.9% 0.0% 28.5% 4.8% 12.0% Inter
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Analysis
Price Target
No Data
